Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) Stock Competitors & Peer Comparison

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SIRO has a market cap of 22B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SIRO trades at $109.97.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SIRO's P/E ratio is 31.88. In terms of profitability, EKSO's ROE is -1.77%, compared to SIRO's ROE of +0.14%. Regarding short-term risk, EKSO is more volatile compared to SIRO. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SIRO's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, HIMS has a market cap of 7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while HIMS trades at $31.59.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas HIMS's P/E ratio is -315.90. In terms of profitability, EKSO's ROE is -1.77%, compared to HIMS's ROE of -0.02%. Regarding short-term risk, EKSO is more volatile compared to HIMS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check HIMS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MMED has a market cap of 5.5B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MMED trades at $19.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MMED's P/E ratio is -25.29. In terms of profitability, EKSO's ROE is -1.77%, compared to MMED's ROE of -0.14%. Regarding short-term risk, EKSO is more volatile compared to MMED. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check MMED's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, OMCL has a market cap of 1.7B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while OMCL trades at $36.81.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas OMCL's P/E ratio is 19.27. In terms of profitability, EKSO's ROE is -1.77%, compared to OMCL's ROE of +0.03%. Regarding short-term risk, EKSO is more volatile compared to OMCL. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check OMCL's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DRTS has a market cap of 1.2B. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DRTS trades at $13.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DRTS's P/E ratio is -19.61. In terms of profitability, EKSO's ROE is -1.77%, compared to DRTS's ROE of -0.73%. Regarding short-term risk, EKSO is more volatile compared to DRTS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check DRTS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MLAB has a market cap of 574.4M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MLAB trades at $102.65.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MLAB's P/E ratio is 10.36. In terms of profitability, EKSO's ROE is -1.77%, compared to MLAB's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to MLAB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check MLAB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LAB has a market cap of 313.2M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LAB trades at $0.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LAB's P/E ratio is -11.43. In terms of profitability, EKSO's ROE is -1.77%, compared to LAB's ROE of -0.18%. Regarding short-term risk, EKSO is more volatile compared to LAB. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LAB's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, STXS has a market cap of 139M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while STXS trades at $1.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas STXS's P/E ratio is -8.35. In terms of profitability, EKSO's ROE is -1.77%, compared to STXS's ROE of -1.53%. Regarding short-term risk, EKSO is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check STXS's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, FONR has a market cap of 117.8M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while FONR trades at $19.09.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas FONR's P/E ratio is 19.09. In terms of profitability, EKSO's ROE is -1.77%, compared to FONR's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to FONR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check FONR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LNSR has a market cap of 74.2M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LNSR trades at $6.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LNSR's P/E ratio is 6.16. In terms of profitability, EKSO's ROE is -1.77%, compared to LNSR's ROE of -5.15%. Regarding short-term risk, EKSO is more volatile compared to LNSR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LNSR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, KDLY has a market cap of 68.1M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while KDLY trades at $11.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas KDLY's P/E ratio is -15.48. In terms of profitability, EKSO's ROE is -1.77%, compared to KDLY's ROE of -0.85%. Regarding short-term risk, EKSO is more volatile compared to KDLY. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check KDLY's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, NEUE has a market cap of 60.9M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while NEUE trades at $6.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas NEUE's P/E ratio is -0.38. In terms of profitability, EKSO's ROE is -1.77%, compared to NEUE's ROE of +0.05%. Regarding short-term risk, EKSO is more volatile compared to NEUE. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check NEUE's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SNWV has a market cap of 50.6M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SNWV trades at $5.88.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SNWV's P/E ratio is 17.82. In terms of profitability, EKSO's ROE is -1.77%, compared to SNWV's ROE of +17.28%. Regarding short-term risk, EKSO is less volatile compared to SNWV. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check SNWV's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, BEAT has a market cap of 29.1M. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while BEAT trades at $0.52.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas BEAT's P/E ratio is -0.94. In terms of profitability, EKSO's ROE is -1.77%, compared to BEAT's ROE of -10.34%. Regarding short-term risk, EKSO is more volatile compared to BEAT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check BEAT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, STSSW has a market cap of 839.4K. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while STSSW trades at $0.03.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas STSSW's P/E ratio is -0.03. In terms of profitability, EKSO's ROE is -1.77%, compared to STSSW's ROE of N/A. Regarding short-term risk, EKSO is more volatile compared to STSSW. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check STSSW's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SPAN has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SPAN trades at $29.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SPAN's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to SPAN's ROE of +0.17%. Regarding short-term risk, EKSO is more volatile compared to SPAN. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SPAN's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, EXAC has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while EXAC trades at $49.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas EXAC's P/E ratio is 3510.33. In terms of profitability, EKSO's ROE is -1.77%, compared to EXAC's ROE of +0.00%. Regarding short-term risk, EKSO is more volatile compared to EXAC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check EXAC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ABCO has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ABCO trades at $0.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ABCO's P/E ratio is 0.52. In terms of profitability, EKSO's ROE is -1.77%, compared to ABCO's ROE of +0.19%. Regarding short-term risk, EKSO is more volatile compared to ABCO. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ABCO's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SCAI has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SCAI trades at $55.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SCAI's P/E ratio is 63.45. In terms of profitability, EKSO's ROE is -1.77%, compared to SCAI's ROE of +0.09%. Regarding short-term risk, EKSO is more volatile compared to SCAI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SCAI's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LDR has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LDR trades at $67.20.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LDR's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to LDR's ROE of +1.17%. Regarding short-term risk, EKSO is more volatile compared to LDR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LDR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MZOR has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MZOR trades at $58.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MZOR's P/E ratio is -70.18. In terms of profitability, EKSO's ROE is -1.77%, compared to MZOR's ROE of -0.14%. Regarding short-term risk, EKSO is more volatile compared to MZOR. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check MZOR's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, MEDC has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while MEDC trades at $0.04.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas MEDC's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to MEDC's ROE of N/A. Regarding short-term risk, EKSO is less volatile compared to MEDC. This indicates lower risk in terms of short-term price fluctuations for EKSO.Check MEDC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, STJ has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while STJ trades at $80.82.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas STJ's P/E ratio is 34.69. In terms of profitability, EKSO's ROE is -1.77%, compared to STJ's ROE of +0.21%. Regarding short-term risk, EKSO is more volatile compared to STJ. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check STJ's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, LPNT has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while LPNT trades at $64.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas LPNT's P/E ratio is 67.44. In terms of profitability, EKSO's ROE is -1.77%, compared to LPNT's ROE of +0.05%. Regarding short-term risk, EKSO is more volatile compared to LPNT. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check LPNT's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, CYNO has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while CYNO trades at $66.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas CYNO's P/E ratio is 105.35. In terms of profitability, EKSO's ROE is -1.77%, compared to CYNO's ROE of +0.03%. Regarding short-term risk, EKSO is more volatile compared to CYNO. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check CYNO's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, PMC has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while PMC trades at $29.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas PMC's P/E ratio is 47.95. In terms of profitability, EKSO's ROE is -1.77%, compared to PMC's ROE of +0.04%. Regarding short-term risk, EKSO is more volatile compared to PMC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check PMC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, ABAX has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while ABAX trades at $83.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas ABAX's P/E ratio is 70.62. In terms of profitability, EKSO's ROE is -1.77%, compared to ABAX's ROE of +0.10%. Regarding short-term risk, EKSO is more volatile compared to ABAX. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check ABAX's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, EVHC has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while EVHC trades at $45.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas EVHC's P/E ratio is -3.20. In terms of profitability, EKSO's ROE is -1.77%, compared to EVHC's ROE of +0.07%. Regarding short-term risk, EKSO is more volatile compared to EVHC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check EVHC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, COTV has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while COTV trades at $44.74.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas COTV's P/E ratio is 26.51. In terms of profitability, EKSO's ROE is -1.77%, compared to COTV's ROE of +0.14%. Regarding short-term risk, EKSO is more volatile compared to COTV. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check COTV's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, AMSG has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while AMSG trades at $67.75.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas AMSG's P/E ratio is N/A. In terms of profitability, EKSO's ROE is -1.77%, compared to AMSG's ROE of +0.08%. Regarding short-term risk, EKSO is more volatile compared to AMSG. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check AMSG's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, SPNC has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while SPNC trades at $38.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas SPNC's P/E ratio is -24.03. In terms of profitability, EKSO's ROE is -1.77%, compared to SPNC's ROE of -0.61%. Regarding short-term risk, EKSO is more volatile compared to SPNC. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check SPNC's competition here

Ekso Bionics Holdings, Inc. (NASDAQ: EKSO) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EKSO stands at 38.6M. In comparison, DSCI has a market cap of 0. Regarding current trading prices, EKSO is priced at $15.90 on the NASDAQ, while DSCI trades at $7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EKSO currently has a P/E ratio of -3.11, whereas DSCI's P/E ratio is -0.02. In terms of profitability, EKSO's ROE is -1.77%, compared to DSCI's ROE of -0.00%. Regarding short-term risk, EKSO is more volatile compared to DSCI. This indicates higher risk in terms of short-term price fluctuations for EKSO.Check DSCI's competition here